Get Alert
Please Wait... Processing your request... Please Wait.
You must sign in to sign-up for alerts.

Please confirm that your email address is correct, so you can successfully receive this alert.

Am J Psychiatry 1990;147:1393-1393.
View Author and Article Information

1990 American Psychiatric Association

text A A A
PDF of the full text article.

In the article "Sertraline in Obsessive-Compulsive Disorder: A Double-Blind Comparison With Placebo," by Michael A. Jenike, M.D., et al. (July 1990 issue, pp. 923-928), there are a number of errors that resulted from incorrect computer entry of the randomization code.The final conclusions of the study are not changed, but a stronger trend toward usefulness of the drug is exhibited. In view of positive data from the multicenter trial of sertraline of which this was one center (G. Chouinard, W. Goodman, J. Greist, et al.: Results of a double-blind placebo controlled trial using a new serotonin uptake inhibitor, sertraline, in obsessive-compulsive disorder. Psychopharmacol Bull [in press]), it is likely that the nonsignificant differences from placebo are due to small sample size.Patients in the placebo and sertraline groups were still similar in clinical characteristics (table 1 in the original paper), and there were few side effects in either group (table 2). The corrected table 3 below summarizes the corrected data analyses, which were done by means of analysis of covariance. All comparisons were nonsignificant beyond p> 0.10. On the Yale-Brown scale, the Maudsley questionnaire, and the global scale, the interaction effect was nonsignificant, so main effects can be unambiguously interpreted. On the NIMH scale, the interaction effect was significant, so main effects could not be unambiguously interpreted; thus, tests of simple main effects were carried out between drug and placebo at each of the five trials. None of the resuls of the tests of simple main effects was significant (all p> O.lO).Also, to clarify a point in the paper, the new drug application requesting that obsessive-compulsive disorder be included as an indication for sertraline will not be submitted for some time, but an application was filed for depression as an indication in 1988 (personal communication, Pfizer Pharmaceutical Company).[See table in the PDF file]

Abstract Teaser
Figures in this Article

Your Session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).




CME Activity

There is currently no quiz available for this resource. Please click here to go to the CME page to find another.
Submit a Comments
Please read the other comments before you post yours. Contributors must reveal any conflict of interest.
Comments are moderated and will appear on the site at the discertion of APA editorial staff.

* = Required Field
(if multiple authors, separate names by comma)
Example: John Doe

Web of Science® Times Cited: 6

Related Content
APA Practice Guidelines > Chapter 0.  >
APA Practice Guidelines > Chapter 0.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 3.  >
Dulcan's Textbook of Child and Adolescent Psychiatry > Chapter 47.  >
The American Psychiatric Publishing Textbook of Psychopharmacology, 4th Edition > Chapter 14.  >
Topic Collections
Psychiatric News
APA Guidelines